MENLO PARK, Calif. — AN2 Therapeutics, Inc. announced the appointment of Cameron Trenor, M.D., as Chief Medical Officer.
Dr. Trenor brings more than 20 years of experience in clinical and translational drug development across hematology, rare diseases, oncology, immunology and metabolic disorders. He has led programs spanning discovery, clinical development, regulatory interactions and commercialization planning.
“We are delighted to welcome Cameron to AN2 Therapeutics,” said Eric Easom, Co-Founder, President and Chief Executive Officer of AN2 Therapeutics. “Cameron’s extensive experience building and leading clinical organizations, advancing innovative therapies through development, and engaging with regulators, investigators and patients will be invaluable as we continue to advance our pipeline. His scientific rigor, patient-centric mindset and proven leadership across both emerging biotechnology companies and large pharmaceutical organizations make him an outstanding addition to our executive team.”
Easom also thanked George H. Talbot, M.D., Co-Founder and Senior Scientific Advisor of AN2 Therapeutics, for leading the company’s clinical programs over the past two years and said Talbot will continue supporting the company during the transition and as a strategic advisor.
Most recently, Dr. Trenor served as Chief Medical Officer of Cellarity, where he helped establish the company’s medical organization as it transitioned into a clinical-stage biotechnology company. He oversaw development of Cellarity’s lead program, including its first investigational new drug application and the launch of a global first-in-human clinical study.
Previously, Dr. Trenor was Executive Medical Director at Forma Therapeutics, which was acquired by Novo Nordisk. There, he led global clinical development activities for etavopivat across multiple indications and supported its advancement from early clinical development into Phase 3.
Earlier in his career, he led clinical and translational programs in hematology and rare diseases at Novartis Institutes for BioMedical Research.
Dr. Trenor also remains a practicing pediatric hematologist-oncologist at Boston Children’s Hospital and has authored about 60 peer-reviewed research publications.
He earned a B.S. in Biology from Tufts University, an M.D. from the University of Tennessee College of Medicine and a Master of Medical Sciences degree in Clinical Investigation from Harvard Medical School. He completed residency and fellowship training through Boston Children’s Hospital, Boston Medical Center and Dana-Farber Cancer Institute and is board-certified in Pediatric Hematology-Oncology.
